ProCE Banner Activity

Update on ADCs and Biomarkers in Breast, Gastrointestinal, and Lung Cancers

Clinical Thought
Commentary by physician experts in breast, gastrointestinal, and lung cancers on key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients.

Released: June 08, 2022

Expiration: June 07, 2023

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Yelena Y. Janjigian

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Program Director Disclosure

Program Director

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Aditya Bardia, MD, MPH, has disclosed that he has received consulting fees from Daiichi Pharma/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, and Sanofi and funds for research support paid to his institution from Daiichi Pharma/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, and Sanofi.

Faculty Disclosure

Primary Author

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Yelena Y. Janjigian, MD, has disclosed that she has received consulting fees from AstraZeneca, Basilea, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Genentech/Roche, Imugene, Lilly, Merck, Merck Serono, RGENIX, Seagen, and Zymeworks; has received funds for research support paid to her institution from Bayer, Bristol-Myers Squibb, Lilly, Merck, and RGENIX; and has stock options from RGENIX.

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Sandip P. Patel, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Genentech, Illumina, Lilly, Merck, Pfizer, Rakuten, and Tempus and funds for research support paid to his institution from Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Fate Therapeutics, Iovance, Lilly, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies.